No news here. Coming quarters project a 500% to 1000% increase in revenue. Today TRVN ran on approval. $BXRX IS Already at Market. This will hit $4.20 and then breakout soon enough.
Here's my "best case scenario:" $BXRX rockets up tomorrow on high volume (it wouldn't take much) & suddenly it's on everyone's radar; spikes to $8-10, gets shorted & eventually settles between $4&5
I'm back in $AGRX approval looks positive for Twirla on Feb 16th (most likely to be announced on February 14th). I've taken a position in $BXRX pending approval on Feb. 20th for meloxicam an opioid-free pain medicine--the FDA should definitely be approving something like this compared to all the opiates they have approved to the detriment of many who have gotten hooked.
For comparison: $PCRX which bread-winner is EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements, has revenues of about $400M. It trades at 4 times revenue.
If as analysts predicts, $BXRX reaches peak revenue of $350M, if you apply an even lower multiple, say 2.5, you'd get to a $875M market cap. If fully diluted we end up with 25M shares --> you'd get at a share price of: 35$ !!!!!!
If Peak sales are overestimated and we just get half of it, PPS should still be, if you follow $PCRX metric at $17!!!!
THAT IS A 630% GAIN FROM TODAY'S PRICE!!!!!!!!!!!!!!!
Aquaman2 months ago $BXRX About 3 month to Q3 results. The price will tank. Nothing to keep it up. -----Well Aquaman, now you pump it when Q3 is still a month away? Hmm, didn't sell those $5 shares like you shoulda
Congrats to any options traders in $TSLA. You really can't complaint about 3000% increase--like once in a lifetime bet, right? I'm in $AGRX with FDA approval for Twirla (birth control patch worn 1 x per week) pending Feb. 14 and $BXRX with FDA approval pending Feb. 20 for major pain-reliever (post-surgery, etc.) without any opiates/opioids.
Top pick for Tuesday
$DOGE
$TRNX
$SNDL
$GSAT
$SEEK
$FCGD
$FTEG
$GARB
$BLSP
$CLBS
$BXRX
If as analysts predicts, $BXRX reaches peak revenue of $350M, if you apply an even lower multiple, say 2.5, you'd get to a $875M market cap. If fully diluted we end up with 25M shares --> you'd get at a share price of: 35$ !!!!!!
If Peak sales are overestimated and we just get half of it, PPS should still be, if you follow $PCRX metric at $17!!!!
THAT IS A 630% GAIN FROM TODAY'S PRICE!!!!!!!!!!!!!!!
And people still sell this stock! smh.
$BXRX
About 3 month to Q3 results. The price will tank. Nothing to keep it up. -----Well Aquaman, now you pump it when Q3 is still a month away? Hmm, didn't sell those $5 shares like you shoulda